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Purpose. To compare the intraocular cytokine and chemokine proﬁles in patients with acute primary acquired ocular toxoplasmosis
(pOT) or recurrent ocular toxoplasmosis (rOT) and to correlate them with their clinical characteristics.Methods. Aqueous humor
samples were collected from 62 consecutive patients (21 pOT, 30 rOT, and 11 noninfected controls) and analyzed by multiplex
assay. Correlations were assessed between cytokine/chemokine levels, type of inﬂammatory response (Th1, Th2, and Th17), and
clinical characteristics. In all OT patients, the clinical diagnosis of either pOT or rOT was conﬁrmed by positive intraocular
Goldmann/Witmer-Desmonts coeﬃcient. Correlations were assessed between a preselected panel of immune mediators and the
clinical characteristics of OT. Results. In pOT patients, increased levels of IL-2, IFN-γ, TNF-α, IL-15, IL-4, IL-5, IL-9, IL-13,
IL-17, IL-1Rα, IL-6, IL-1β, and chemokines MIP-1α, MIP-1β, IP-10, Eotaxin, IL-8, RANTES, PDGF-bb, GM-CSF, G-CSF, and
MCP-1 were found in comparison to those in controls (p < 0 05). Patients with rOT showed elevated levels of IL-2, IFN-γ,
TNF-α, IL-15, IL-4, IL-5, IL-9, IL-17, IL-1Rα, IL-6, IL-1β, and chemokines MIP-1α, IP-10, Eotaxin, IL-8, RANTES, PDGF-bb,
G-CSF, and MCP-1 compared to controls (p < 0 05). In addition, IL-7 (p = 0 028) diﬀered between pOT and rOT; IL-9
(p = 0 054) and IL-13 (p = 0 051) showed a tendency of higher concentration in pOT than in rOT. A negative correlation was
found between IL-7 (p = 0 017) as well as IL-9 (p = 0 008) and the number of recurrences. Cytokine ratios showed no diﬀerence
between pOT and rOT, indicating a dominant Th1-type response in both infectious groups. Moreover, a positive correlation was
detected between IL-7, VEGF, IL-13 and age at aqueous humor sampling (p < 0 05). Conclusions. This study for the ﬁrst time
shows subtle diﬀerences between the intraocular cytokine proﬁles in patients with either acute pOT or rOT.
1. Introduction
The protozoan Toxoplasma gondii (T. gondii) establishes a
lifelong chronic infection that targets neuronal tissues such
as the brain and the retina. Ocular toxoplasmosis (OT)
remains one of the leading causes of visual impairment and
is the most frequent cause of infectious posterior uveitis [1].
It typically presents with focal inﬂammation and necrosis of
the neurosensory retina, aﬀecting retinal glial and pigment
epithelial cells [2]. The severity of OT varies mainly due to
the genotype of the pathogen, the genetic background of
the patient and its immune response. The genotype of
the pathogen has been recognized for some time, as more
virulent strains with pronounced clinical manifestations
are observed, in particular in South America compared to
Europe [1, 3]. This impacts the immune response and clinical
course of T. gondii infections. During the acute stage of the
infection, an intraocular IFN-γ-mediated immune response
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and, to a lesser degree, humoral immunity limit parasite
growth induced conversion of tachyzoites to dormant brady-
zoites. But the parasite eventually establishes a chronic infec-
tion leading to a lifelong risk of exacerbation with
signiﬁcant threat for visual impairment and psychological
burden [4].
While the physiopathological mechanisms that lead to
reactivation of OT are not yet fully understood, the intraocu-
lar immune response plays an essential role [5]. Subse-
quently, mapping of intraocular mediators has become a
ﬁeld of major interest since it may provide better guidance
for more targeted treatment and prognostic outcome. Thus,
a predominant Th2 response has been related to a more
severe clinical manifestation in a cohort of 9 Columbian
patients. In the same study, IL-5 and VEGF were associated
with more frequent recurring OT [6]. In contrast, high levels
of IFN-γ, IL-6 and MIP-1 indicating a strong Th1 immune
response have been consistently reported in Europe. Taken
together, a ﬁrst “ﬁngerprint” of the immune response is
emerging and potentially may serve as a “biomarker” with
further clinical importance [6]. Nevertheless, contradictory
results persist, which are related to (a) diﬀerences in the OT
strain—host interaction—(b) the stage of the ocular dis-
ease, and (c) often the insuﬃcient number of patients. In par-
ticular, to our knowledge, there exists no reliable information
regarding the distinction between the initial manifestation
and further occurring reactivation of OT. Although reactiva-
tion of OT is considered as an important problem, none of
the previous studies have diﬀerentiated between acute pri-
mary (pOT) and recurrent OT (rOT) in European patients.
So far, there is virtually no data available diﬀerentiating
between the intraocular milieu in patients with acute pOT
and rOT. It has been suggested that the intraocular cytoki-
nome provides a rationale to delineate potential options to
intervene and prevent further disease progression.
Therefore, here, we evaluated the intraocular immune
response in patients with active pOT and rOT. We not only
investigated whether there is a diﬀerence in these two clinical
cohorts but also correlated the intraocular expression of
inﬂammatory mediators with clinical ﬁndings. Our results
indicate for the ﬁrst time that the cytokinome diﬀers in active
pOT and rOT and may open further avenues for guidance on
severity and risk of recurrence in this infection.
2. Methods
2.1. Study Populations. All 51 OT patients and 11 controls
were seen by an experienced ophthalmologist (UP). They
underwent a complete ocular exam including best corrected
Snellen visual acuity, slit lamp biomicroscopy, tonometry,
indirect ophthalmoscopy, OCT and visual ﬁeld testing. The
diagnosis of OT was (a) based on retina visualization by
binocular ophthalmoscopy with a +20-diopter lens (Volk
Corporation, USA) and (b) secured by biological testing
of intraocular ﬂuids as previously reported [7, 8].
All patients were seen between December 2005 and April
2014 at Charité-Universitätsmedizin Berlin, Department of
Ophthalmology, a tertiary referral and uveitis center. All
subjects were immunocompetent without a past medical
history of immune modulatory or cytotoxic agents. Since
patient age has been discussed as a confounding factor
in OT recurrences, we arbitrary allocated patients being
either younger or older than 40 years.
2.1.1. Patients with Acute Primary Ocular Toxoplasmosis.
Acute pOT was deﬁned as the presence of an active lesion
(creamy white, focal retinal lesion) not associated with reti-
nochoroidal scars in either eye following the internationally
accepted diagnostic criteria [9].
2.1.2. Patients with Acute Recurrent Ocular Toxoplasmosis.
Acute rOT was deﬁned as the presence of such an active
lesion and at least one hyperpigmented retinochoroidal scar
formation due to OT [9]. Episodes of anterior segment
inﬂammation in the eyes with retinochoroidal scars without
active retina lesions were not considered as recurrences and
excluded. There was only one patient with congenital
acquired OT.
2.1.3. Control Group. The control group consisted of 11
patients who had undergone routine cataract surgery.
These individuals had no preexisting ocular disease, except
cataract; in particular, they had no lesion suspicious for
previous intraocular infection, nor previous ocular surgery.
Samples of aqueous humor were obtained initially at cata-
ract surgery and proved negative for intraocular T. gondii
antibody synthesis.
2.2. Clinical Evaluation and Intraocular Inﬂammation
Assessment. In all patients, we graded the level of inﬂamma-
tion based on the presence of cells in the anterior chamber
and/or vitreous haze (grade 0-IV) according to the criteria
proposed by the International Uveitis Study Group (IUSG)
and Standardization of Uveitis Nomenclature (SUN) [10].
To document the location and size of retina lesions, fundus
photographs were taken by a Zeiss Fundus camera FF 450
plus (Zeiss, Jena, Germany) and the size of retinochoroidal
lesions was measured in optic disc diameters.
2.3. Sample Collection and Processing. Following informed
consent, aqueous humor sampling was undertaken under
topical anesthesia. All procedures were performed under
aseptic conditions in an ocular surgery setting. Brieﬂy, a
31-gauge needle was inserted at the peripheral clear cornea
and between 100 and 300μl aqueous humor could be with-
drawn under direct control of an operating microscope [8].
All samples were immediately stored and maintained at
-80°C to prevent degradation and thawed directly before
analysis.
2.4. Measurement of Immune Mediators in Aqueous Humor
Samples. The Bio-Plex Pro Human Cytokine 27-Plex
Immunoassay (Bio-Rad) was used to measure concentrations
of immune mediators in the aqueous humor samples. The
immune mediators were classiﬁed into 8 categories: the T cell
development-promoting cytokines, Th1-derived cytokines,
Th1 cell development-promoting cytokines, Th2-derived
cytokines, Th17-derived cytokines, Th17 cell development-
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promoting cytokines, chemokines, and growth, angiogenetic
and wound-healing factors.
The layout of the assay consisted of eight standards in
duplicate, two blank wells, and 62 aqueous humor samples.
Levels of immune mediators were calculated in pg/ml using
standard curves of known concentrations. The data were
analyzed with Bio-Plex Manager software, version 1.1. All
measurement values were extrapolated beyond standard
ranges to calculate concentrations by 5-parameter logistic
regression, and these were used for statistical comparisons
by nonparametric testing.
2.5. Ethical Considerations. The study followed the tenets of
the Declaration of Helsinki and was approved by the institu-
tional ethics committee of Charité. All patients provided
written informed consent and the institutional review board
of ethics approved this study (registration number 8/6109).
2.6. Statistical Analysis. The software GraphPad Prism Ver-
sion 7.04 was used for the statistical analysis to compare
immune mediator levels of the three groups (pOT, rOT,
and controls) by Kruskal-Wallis test followed by uncorrected
Dunn’s test. We did not correct for multiple comparisons
in order to not inﬂate type II errors in this exploratory
study. To detect correlations between clinical parameters
and immune mediator levels, Spearman rank correlation
was applied. Since ratios of immune mediators, e.g. the
TNF-α/IL-10 relation, have been previously supportive in
determining the signiﬁcance of particular pathways, the fol-
lowing cytokine ratios were formed: IFN-γ/IL-4, IFN--
γ/IL-10, IL-17/IFN-γ, TNF-α/IL-10, and IL-12p70/IL-10.
We added one to all cytokine values relevant for the cytokine
ratio in order to avoid zero values.
The Poisson test was used for the calculation of the
risk of recurrence using IBM SPSS Statistics Version 19.
Boxplots and graphs were created with the software
GraphPad Prism Version 7.04 [11]. To analyze the frequency
of age distribution between groups, the chi-square test was
performed [12]. A statistically signiﬁcant result was deﬁned
as p ≤ 0 05.
Table 1: Clinical characteristics of the patient in the primary and recurrent OT groups and control group.
Primary OT Recurrent OT Control group p valuea
Number of patients (n) 21/62 (33.9%) 30/62 (48.4%) 11/62 (17.7%)
Gender Male: 42.9% (9/21) Male: 36.6% (11/30) Male: 63.6% (7/11)
Interval between consultation and
aqueous humor sampling (days)
2 ± 2 3 ± 4
Observation time after aqueous
humor sampling (days)
143 ± 250 577 ± 852
Mean age at ﬁrst episode (years ± SD) 39 ± 15 30 ± 15 p = 0 043
Mean age at aqueous humor sampling
(years ± SD) 39 ± 15 38 ± 15 75 ± 7
pOT/rOT vs control:
p < 0 001, pOT vs
rOT: p = 0 821
Age < 40 years: 18 patients
Age > 40 years: 12 patients
Median grading of inﬂammation in
vitreous humor (grade 0-4, min.-max.)
1 (1-3) 0.8 (0.8-2)
Median grading of inﬂammation in the
anterior chamber (grade 0-4, min.-max.)
0 (0-2) 0 (0-3)
Median number of active lesions
(n, min.-max.)
1 (1-1) 1 (1-4)
Median size of active lesions
(PD, min.-max.)
1 (0-3) 0.3 (0-8) p > 0 05
Median number of scars (n, min.-max.) 0 1 (1-7)
Bilateral OT involvement 0 20% (6/30)
Median number of recurrent active
episodes (n)
∅ 1.5 (1-18)
Age < 40 years: 2 recurrences
Age > 40 years: 1 recurrence p = 0 032
Macular involvement 9.5% (2/21) 13.3% (4/30)
Risk of recurrences
Age < 40 years: 2.34 times
higher than >40 years p = 0 007
A summary of the patients’ demographics and clinical characteristics in the primary and recurrent OT groups and control group. OT: ocular toxoplasmosis; SD:
standard deviation; PD: diameter of the papilla; ap value < 0.05 is considered as statistically signiﬁcant; signiﬁcant p values are shown in bold.
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3. Results
3.1. Patient Demographics. We enrolled 51 individuals with
clinical characteristics of OT and additional serological intra-
ocular conﬁrmation of the infection. Based on the predeﬁned
diagnostic criteria, 21 patients presented with pOT, whereas
30 individuals suﬀered from rOT [9]. The mean age at the
ﬁrst episode of ocular infection was 39 ± 15 years in the
pOT group and 30 ± 15 years in the rOT group. The age at
aqueous humor sampling was 39 ± 15 years in the pOT group
and 38 ± 15 years in the rOT group. No diﬀerence in age was
present in both OT cohorts, but as can be expected, individ-
uals undergoing cataract surgery (controls) were older (mean
age: 75 ± 7 years; p < 0 001, Table 1). The rate of recurrences
was more than 2 times higher in patients less than 40 years of
age (Table 1).
3.2. Clinical Findings and Grading of Intraocular
Inﬂammation. The clinical characteristics of all participants
are summarized in Table 1. Brieﬂy, all OT patients presented
typically with active retinochoroiditis with whitish, mod-
erately exudative, ill-deﬁned retina lesions (100%) [1, 9].
Of interest, bilateral OT was rare and exclusively seen
in few (n = 6) patients with recurrent ocular lesions. How-
ever, at no time, simultaneous inﬂammatory activity was
observed.
Inﬂammation in the anterior chamber ranged from 0 to
+2 in both OT groups and did not diﬀer signiﬁcantly in
pOT (median grade: 0) compared to rOT (median grade:
0), even when pOT patients were more often aﬀected (32%
vs. 24% in rOT). Similarly, vitreous haze was not only more
frequently seen in pOT (46% vs. 24% in rOT) but also
appeared as more intense at initial infection (pOT: grade
1-3 as compared to rOT: grade 0.8-2). Both ﬁndings, how-
ever, did not prove to be signiﬁcant. Finally, we documented
a wide range in the size of retina lesions, which extended for
up to 8 disc diameters but we were unable to detect a statis-
tically signiﬁcant diﬀerence between groups (pOT vs. rOT,
p > 0 05).
3.3. Comparison of Immune Mediator Concentrations in
pOT, rOT, and Controls. A panel of immune mediators was
signiﬁcantly upregulated in patients aﬀected by acute pOT.
This includes cytokines of the Th1 response. Tables 2 and 3
Table 2: Chemokine, growth factor, angiogenetic factor, and wound healing factor concentration in aqueous humor of a control group and
patients with pOT and rOT (n = 62).
Immune mediator
Mdn concentration
in patients with pOT,
n = 21 (IQR) (pg/ml)
Mdn concentration
in patients with rOT,
n = 30 (IQR) (pg/ml)
Mdn concentration in
patients in the control group,












IL-2 183 (0, 315) 123 (0, 233) 0 (0, 0) <0.001 0.003 0.324
Th1-cytokines
IFN-γ 760 (218, 2.93∗103) 348 (62.7, 909) 0 (0, 0) <0.0001 <0.001 0.129
TNF-α 55.2 (15.6, 111.4) 22.6 (4.53, 64.9) 0 (0, 0) <0.00001 <0.001 0.104
Th1 cell development-
promoting cytokines
IL-12p70 233 (114, 423) 132 (81.2, 289) 192 (158, 384) 0.761 0.205 0.241
IL-7 654 (464, 1.19∗103) 450 (318, 937) 772 (532, 851) 0.916 0.097 0.028
IL-15 79.8 (39.9, 217) 47.5 (12.5, 136.5) 0 (0, 23.4) <0.0001 0.004 0.084
Th2 cytokines
IL-4 29.4 (4.48, 59.6) 16.2 (0, 38.6) 0 (0, 0) <0.0001 <0.001 0.183
IL-5 49.2 (22.8, 149) 37.1 (15.5, 93.6) 0 (0, 0) <0.0001 <0.001 0.380
IL-9 135 (58.7, 345) 93.5 (14.9, 205) 0 (0, 0.62) <0.00001 0.001 0.054
IL-10 67.9 (2.43, 176) 19.8 (0, 102) 1.99 (1.59, 49.8) 0.106 0.521 0.188
IL-13 345.4 (204, 1.05∗103) 194 (77.9, 647) 230 (103, 286) 0.022 0.402 0.051
Th17 cytokines
IL-17 79.9 (0, 371) 0 (0, 234) 0 (0, 0) 0.001 0.014 0.237
IL-1Rα 262 (53.5, 648) 130 (0, 337) 0 (0, 0) <0.0001 0.002 0.207
Th17 cell development-
promoting cytokines
IL-6 2.74∗103 (738, 6.01∗103) 1.06∗103 (173, 3.99∗103) 150 (1.54, 409) <0.0001 0.004 0.108
IL-1β 3.96 (0.57, 8.11) 1.38 (0, 5.36) 0 (0, 1.49) 0.003 0.032 0.220
pOT: primary OT; rOT: recurrent OT: Mdn: median; IQR: interquartile range; signiﬁcant p values are shown in bold; italic values are below LLOQ as deﬁned by
the manufacturer.
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summarize the data of all inﬂammatory mediators detected
in the aqueous humor of all three cohorts. Comparing pOT
and controls, the following immune mediators were signiﬁ-
cantly elevated: IL-2 (p < 0 001), IFN-γ (p < 0 0001), TNF-α
(p < 0 00001), IL-15 (p < 0 0001), IL-4 (p < 0 0001), IL-5
(p < 0 0001), IL-9 (p < 0 00001), IL-13 (p = 0 022), IL-17
(p = 0 001), IL-1Rα (p < 0 001), IL-6 (p < 0 0001), IL-1β
(p = 0 003), MIP-1α (p < 0 001), MIP-1β (p = 0 023), IP-10
(p < 0 00001), Eotaxin (p < 0 001), IL-8 (p < 0 001), RANTES
(p < 0 0001), PDGF-bb (p < 0 001), GM-CSF (p = 0 036),
G-CSF (p = 0 004), and MCP-1 (p < 0 001). When we
analyzed and compared rOT and controls, the following
spectrum appeared as given in detail: IL-2 (p = 0 003),
IFN-γ (p < 0 001), TNF-α (p < 0 001), IL-15 (p = 0 004),
IL-4 (p < 0 001), IL-5 (p < 0 001), IL-9 (p = 0 001), IL-17
(p = 0 014), IL-1Rα (p = 0 002), IL-6 (p = 0 004), IL-1β
(p = 0 032), MIP-1α (p < 0 001), IP-10 (p < 0 0001), Eotaxin
(p = 0 007), IL-8 (p = 0 009), RANTES (p < 0 001), PDGF-
bb (p = 0 001), G-CSF (p = 0 034), and MCP-1 (p = 0 009)
(Figures 1-3 and Supplementary Figures 1-3). When both
groups of infected patients were compared (pOT vs. rOT),
we detected IL-7 as elevated in pOT (p = 0 028) (Table 2,
Figure 2). IL-9 (p = 0 054) and IL-13 (p = 0 051) showed a
tendency of being elevated in pOT when comparing both
infectious groups (Table 2).
Since the balance between pro- and anti-inﬂammatory
mediators is important in OT, we calculated the ratios of
key regulators. All cytokine ratios showed no signiﬁcant
diﬀerence between pOT and rOT, indicating a dominant
Th1-type response in both infectious groups: IFN-γ/IL-4
(p = 0 054), IFN-γ/IL-10 (p = 0 405), IL-17/IFN-γ (p =
0 499), TNF-α/IL-10 (p = 0 783), and IL-12p70/IL-10 (p =
0 291) did not reveal any shift of the immune response
between pOT and rOT (Table 4).
3.4. Correlations between Immune Mediator Concentration
and Clinical Characteristics. As a second goal, we analyzed
whether there is a correlation between expression of
immune mediators and clinical manifestations. Even when
inﬂammation was remarkable and appeared even more
intense in our pOT individuals, we were not able to correlate
intraocular ﬁndings, e.g. vitreous haze, with a particular
pattern of inﬂammatory mediators. Similarly, we could not
correlate the OT lesion size with any intraocular immune
mediator (p > 0 05). Whereas this is in line with previous
observations in European studies, further ﬁndings relate to
our major interest, the association of OT recurrences to
other variables.
Interestingly, a negative correlation between IL-9 (p =
0 008), IL-7 (p = 0 017) and number of OT recurrences could
be detected (Figure 4). The concentration of several other
immune mediators was reduced with the number of OT
recurrences (Supplementary Table 1). In particular, there
were two patients with 18 and 10 OT recurrences who
showed an overall reduced immune mediator concentration.
In addition, our ﬁndings further indicate a positive corre-
lation between age at consultation and concentration of IL-7
(p = 0 018), VEGF (p = 0 031) and IL-13 (p = 0 030).
As noted earlier, in our rOT group, patients younger than
40 years of age experienced a higher number of recurrences
Table 3: Chemokines, growth factor, angiogenetic factor, and wound healing factor concentrations in aqueous humor of a control group and
patients with pOT and rOT (n = 62).
Immune mediator
Mdn concentration
in patients with pOT,
n = 21 (IQR) (pg/ml)
Mdn concentration
in patients with rOT,
n = 30 (IQR) (pg/ml)
Mdn concentration
in patients in the
control group,











MIP-1α 271 (134, 412) 157 (56.7, 451) 0 (0, 41.2) <0.0001 <0.001 0.331







(3.17∗103, 13.0∗104) <0.00001 <0.0001 0.235
Eotaxin 925 (241, 1.32∗103) 755 (0, 1.01∗103) 1.95 (0, 290) <0.001 0.007 0.302
IL-8 280 (128, 937) 120 (51.6, 611) 56.5 (0, 90.2) <0.001 0.009 0.166
RANTES 219 (61.3, 296) 91.1 (7.4, 372) 0 (0, 0) <0.0001 <0.001 0.366
PDGF-bb 288 (63.8, 598) 164 (0, 419) 0 (0, 0) <0.001 0.001 0.378
Growth, angiogenetic, and wound
healing factors
GM-CSF 0 (0, 169) 0 (0, 98.7) 0 (0, 0) 0.036 0.067 0.639





(1.05∗103, 2.41∗103) 958 (667, 1.34∗10
3) <0.001 0.009 0.151
VEGF
1.13∗103
(394, 1.78∗103) 908 (246, 1.85∗10
3)
1.29∗103
(828, 1.68∗103) 0.746 0.469 0.637
FGF basic 38.2 (2.87, 80.6) 27.6 (0.67, 60.4) 0 (0, 57.5) 0.066 0.245 0.333
pOT: primary OT; rOT: recurrent OT, Mdn: median, IQR: interquartile range: signiﬁcant p values are shown in bold; italic values are below LLOQ as deﬁned by
the manufacturer.
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when compared to individuals above the 4th life decade
(patients < 40 years of age: mean = 3 6 ± 4 4 recurrences,
median = 2 recurrences; patients > 40 years of age: mean =
2 1 ± 2 8 recurrences, median = 1 recurrences, p = 0 032).
According to the incidence rate ratio, patients < 40 years
of age bear a 2.34 times higher risk for recurrence than
patients > 40 years of age (Tables 1, 95% CI 1.38-4.11, p =
0 007). Consequently, we were able to calculate the
recurrence rate in the group aged below 40 years as
0.385 per person per year, whereas the recurrence rate
in the older group dropped to 0.164 per person per year.
Two patients of our cohort show exemplarily the reduc-
tion of immune mediator levels in aqueous humor: a
28-year old male patient who had 18 OT recurrences
with extensive immune mediator reduction (Figure 5)
and a 33-year old female patient with congenital OT
who had 2 OT recurrences and revealed low IFN-γ levels,
still with high concentrations of IP-10, IL-6, MCP-1, and
VEGF (Figure 6).
4. Discussion
Aqueous humor is important for the homeostasis of the eye,
and it reﬂects the “milieu interior.” Therefore, it is used in
diagnosis and to investigate immune-mediated changes [13,
14]. Although recovery of aqueous humor is not a harmful
procedure, it is not routinely performed in most uveitis cen-
ters. Thus, currently, only very limited information is avail-
able on intraocular cytokine proﬁles in patients with OT.
In this study, we compared the intraocular cytokine
proﬁles of acute pOT and rOT for the ﬁrst time. Increased
levels of IFN-γ, TNF-α, IL-4, IL-17, IL-6, MIP-1α, MIP-1β,
IP-10, IL-8, RANTES, and MCP-1 were detected in both
primary and recurrent OT compared to controls. Interest-
ingly, immune mediator release was reduced with the num-
ber of recurrences.
The immune response in active OT is initiated by the
recognition of the parasite, which stimulates the produc-





















































































p = 0.104 p = 0.235 
p = 0.324
Figure 1: Box plot depicting the proﬁle of the T cell development-promoting cytokine IL-2 and Th1-derived cytokines IFN-γ and TNF-α and
the chemokine IP-10 in aqueous humor of patients with pOT (n = 21) and rOT (n = 30) and the control group (n = 11).
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including NK cells and macrophages [15, 16]. These cells
and mediators control local inﬂammation and dissemination
of tachyzoites. Furthermore, a Th1-cell-dominated adaptive
immune response rapidly controls the dividing tachyzoite
stage of T. gondii [17]. Indeed, in our patients with pOT
and rOT, we conﬁrmed a dominant Th1-type response with
increased expression of IFN-γ and TNF-α. Both cytokines
are produced through resident and immune cells and act
synergistically by inhibiting T. gondii replication in retinal
pigment epithelial (RPE) cells. However, only IFN-γ sup-
presses the parasite within retinal glial cells and it remains
undoubtedly the dominant player in antitoxoplasmic immu-
nity [2]. If IFN-γ is absent, the risk for recurrent exacerba-
tions of the infection is increased [18, 19].
TNF-α contributes to upregulation of IFN-γ, and in
an experimental mouse model, it played an important
protective role in T. gondii infection [20]. In our patients,
levels of TNF-α were more signiﬁcantly elevated in the
ﬁrst OT episode. IL-6, another cytokine that promotes
IFN-γ upregulation, was also highly expressed in pOT
and, to a lesser extent, in rOT. IL-6 has pleiotropic eﬀects
that can be both protective and deleterious during T.
gondii infection and be pathologic in OT [18, 21, 22]. It
leads to signiﬁcant local recruitment of neutrophils,
monocytes and T lymphocytes with destructive eﬀects on
retinal architecture [21]. In addition, it downregulates
transforming growth factor-β, a cytokine that plays a key
role in maintaining ocular immune privilege [23, 24] and
contributes to induction of intraocular IL-17, another pro-
inﬂammatory cytokine for which both protective and
destructive eﬀects have been reported [25–28]. It has been
suggested that increased IL-17 could be related to the
often more favorable clinical course in European patients
versus South Americans [25]. Two studies examining intra-
ocular cytokines in French patients revealed Th1- and
Th17-type responses, whereas de-la-Torre et al. [25] found
that Columbian patients showed predominantly Th2-type
immune responses, mainly related to divergent T. gondii
genotypes [25, 26]. Our ﬁndings were similar to those in
the French patients, with dominant Th1- and Th17-type
responses [20, 22].
Although the IFN-γ-mediated immune response is
dominant in OT, Th2-type cytokines such as IL-4 and IL-13
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Figure 2: Box plots depicting the cytokine patterns of Th1 cell development-promoting cytokines IL-12p70 and IL-7 and the Th2-derived
cytokines IL-4 and IL-9 in aqueous humor comparing results of patients with pOT (n = 21) and rOT (n = 30) and the control group
(n = 11).
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anti-inﬂammatory mediators such as IL-10 is also important
[30]. Compared to the control group, we found elevated
aqueous humor levels of IL-4 in pOT and rOT and of IL-13
in pOT. However, the Th1-type response seems to be
dominant in pOT and rOT, as shown by the cytokine ratios
(Table 4). We have also shown for the ﬁrst time in pOT
and rOT the intraocular presence of IL-9, a cytokine pro-
duced by Th2, Th9, and Th17 cells. There was a tendency
to more elevated IL-9 and IL-13 in pOT than in rOT
(Table 2), suggesting the possibility that the intraocular
absence of these cytokines may play a role in OT recur-
rence. IL-9 plays a role in various parasite infections [31],
and the role of IL-9 in protection against T. gondii merits
further investigation.
Chemokines play a major role in OT, selectively recruit-
ing monocytes, neutrophils and lymphocytes [32, 33].
CXCL10 had very high levels in both our OT cohorts. Also
known as IP-10, it is mainly secreted by monocytes, endothe-
lial cells and ﬁbroblasts, attracts monocytes/macrophages, T
cells, NK cells, and dendritic cells, and upregulates the
Th1-type immune response. In addition, we found increased
levels of CCL2 (MCP-1), CCL3 (MIP1-α), and RANTES in
all OT patients.
An obvious question is whether the immune mediator
proﬁle correlates with clinical features. Whereas clinical ﬁnd-
ings such as size of retinal lesions, extent of inﬂammation,
and vitreous inﬁltration could not be correlated to any cyto-
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Figure 3: Cytokine patterns of the Th2 cytokine IL-10, the Th17 cell development-promoting cytokine IL-6, the Th17-derived cytokine IL-17,
and the chemokine IL-8 comparing immune mediator concentrations in aqueous humor of patients with pOT (n = 21) and rOT (n = 30) and
the control group (n = 11).
Table 4: All ﬁve cytokine ratios (IFN-γ/IL-4, IFN-γ/IL-10, IL-17/IFN-γ, TNF-α/IL-10, and IL12p70/IL-10) indicate a dominant Th1-type
immune response.







IFN-γ/IL-4 1 29.2 18.1 <0.001 0.004 0.212
IFN-γ/IL-10 0.39 16.7 6.55 <0.0001 <0.001 0.405
IL-17/IFN-γ 1 0.11 0.24 <0.001 0.002 0.499
TNF-α/IL-10 0.33 0.93 1 0.004 0.005 0.783
IL-12p70/IL-10 29.1 3.72 5.44 0.004 0.031 0.291
OT: ocular toxoplasmosis; Mdn: Median: signiﬁcant p values are shown in bold.
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Figure 4: Correlation between cytokine levels and number of recurrences for IL-9 (p = 0 008) and IL-7 (p = 0 017) in aqueous humor of






































Figure 5: Bar chart showing the pattern of immune mediators in aqueous humor of a patient who had 18 recurrences with generally low
immune mediator levels in aqueous humor and elevated levels of IP-10, and concentrations of MCP-1, MIP-1β, IL-7, and IL-6 are detectable.
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relevance. In our study, the concentration of IL-7 in aqueous
humor was low in patients with rOT, with an additional
trend towards low IL-9 and IL-13, which may suggest a role
for those cytokines in preventing recurrence. A prospective
study evaluating the concentrations of cytokines over the
course of OT may clarify whether low levels of these cyto-
kines could predict rOT.
Our study found a higher number of recurrences in the
overall cohort compared to a recent study in Columbia by
de-la-Torre et al. [6]. In particular, the number of recur-
rences in our study cohort was more than 2-fold higher in
our patients younger than 40 years. The results of another
study with European patients corresponded with ours,
revealing that younger OT patients have a higher risk of
recurrences than older OT patients [34]. Contrary to this,
Holland et al. [35] found that patients > 40 years of age have
a higher risk of recurrence than younger patients. The aver-
age age of our entire study cohort was slightly higher com-
pared to that of de-la-Torre et al. [6]; however, the age of
our rOT patients was comparable to previous reports [1, 6].
Whereas age did not prove as a confounding factor of
intraocular immune mediator expression in previous studies,
its role for OT recurrences is still under debate [24, 36]. Inter-
estingly, our patients < 40 years of age had a higher number
of recurrences and a higher risk of recurrences (Table 1). It
is likely that T. gondii attempts to skew the local immune
response further down in order to evade the host response
and favor its survival and replication.
Whereas the intraocular cytokinome could not be corre-
lated with clinical features, VEGF levels increased with age
at aqueous humor sampling in our study cohort. VEGF
was previously found to correlate with inactive OT and
was suggested to play a role in the formation of neovascular
membranes following T. gondii infection [6].
Taking into account regional diﬀerences, large cohorts
from diﬀerent regions of the world might be necessary to
extend our observations on diﬀerences between pOT and
rOT. The genotype of the pathogen was not analyzed in
detail in our study; however, we previously identiﬁed type
II as dominant in our patients [3]. The current investigation
is limited by the cross-sectional design, in which all sub-







































Figure 6: Bar graph showing the proﬁle of immune mediators in aqueous humor of a patient with congenital recurrent OT who had 2
recurrences with low IFN-γ levels, but high levels of IP-10, IL-6, MCP-1, and VEGF.
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Although the acute response is probably most important to
guide the subsequent clinical course of ocular infection, a
follow-up study with aqueous samplings over the course of
OT may give us more insightful information regarding the
pathogenesis of the disease. We did not sample aqueous
humor from OT patients during the quiescent stage of infec-
tion for ethical reasons. However, in future studies, it would
be valuable to analyze the aqueous humor of OT individuals
who need to undergo surgery for other reasons, e.g., the
development of cataracts. Similarly, it would be ideal to sam-
ple aqueous humor from a larger cohort of healthy individ-
uals with no ocular pathology to serve as controls and it
should be stressed that the ﬁndings in this exploratory study
need to be validated in new cohorts of samples.
In summary, our study indicates that the cytokinome
in pOT and rOT has subtle diﬀerences and that immune
mediator levels in aqueous humor decline with recurrences.
Moreover, young patients in our cohort had a higher risk
of recurrences for OT. Mapping of mediators may there-
fore not only strengthen our understanding of the intraoc-
ular pathophysiology of this sight-threatening infection but
provide guidance on more speciﬁc treatment options and
prognostic evaluation.
5. Summary
Whereas a strong Th1-type-mediated immune response
dominated in primary ocular toxoplasmosis and recurrent
ocular toxoplasmosis, subtle diﬀerences in a number of
immune mediators could be found between both cohorts.
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